Literature DB >> 2295271

Comparison of computed tomography and contrast enema evaluation of diverticulitis.

T R Smith1, K C Cho, H T Morehouse, P S Kratka.   

Abstract

A total of 31 patients with diverticulitis were analyzed who had both computed tomography and contrast enema. There was almost equal sensitivity to abnormality of approximately 90 percent. Contrast enema produced a specific diagnosis of diverticulitis in 61 percent, using stringent positive criteria, and an additional 29 percent with suggestive findings. Comparative computed tomography specific diagnoses in those 31 cases was made in 65 percent, and suggestive in 23 percent. Computed tomography was particularly useful diagnostically in cases of retrograde obstruction on contrast enema. The authors conclude that contrast enema should be the primary mode of approach, while computed tomography can be a valuable follow-up when the diagnosis is still in doubt, or if it is possible that patient management might be altered by additional information.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295271     DOI: 10.1007/bf02053191

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  3 in total

1.  Acute localized diverticulitis: optimum management requires accurate staging.

Authors:  R Detry; J Jamez; A Kartheuser; F Zech; R Vanheuverzwijn; P Hoang; P J Kestens
Journal:  Int J Colorectal Dis       Date:  1992-02       Impact factor: 2.571

2.  Elective vs. early elective surgery in diverticular disease: a retrospective study on the optimal timing of non-emergency treatment.

Authors:  Felix Benjamin Warwas; Berthold Schneider
Journal:  Int J Colorectal Dis       Date:  2018-03-13       Impact factor: 2.571

3.  Graded compression ultrasonography and computed tomography in acute colonic diverticulitis: meta-analysis of test accuracy.

Authors:  Wytze Laméris; Adrienne van Randen; Shandra Bipat; Patrick M M Bossuyt; Marja A Boermeester; Jaap Stoker
Journal:  Eur Radiol       Date:  2008-06-04       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.